The FDA has approved a new drug for a serious heart condition that affects thousands of people. The drug, called Amvuttra ...
The Food and Drug Administration (FDA) has approved Amvuttra ® (vutrisiran) for the treatment of the cardiomyopathy of ...
Investor's Business Daily on MSN4d
Alnylam Jumps As A New Approval Sets Up Its Next Battle With Pfizer, BridgeBioAlnylam stock jumped Friday after the drugmaker won a second Food and Drug Administration approval for its drug, Amvuttra.
CM, expanding its market reach. JP Morgan upgrades the stock, projecting strong sales and a multi-billion opportunity.
Amvuttra’s clearance in a rare form of cardiomyopathy could help Alnylam turn a regular profit — if it can wrest control of a ...
Alnylam Pharmaceuticals has secured FDA approval for Amvuttra in ATTR-CM, opening the door to potential revenue of over $6B. The company's strong R&D pipeline, including promising candidates like ...
Despite growing competition in the transthyretin amyloid cardiomyopathy (ATTR-CM) field, Alnylam is hoping its RNA interference approach can set it apart from its peers. | Despite growing competition ...
Zacks Investment Research on MSN1d
Alnylam (ALNY) Surges 11.8%: Is This an Indication of Further Gains?Alnylam Pharmaceuticals (ALNY) shares soared 11.8% in the last trading session to close at $283.34. The move was backed by solid volume with far more shares changing hands than in a normal session.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback